Hepatitis Monthly

Published by: Kowsar

Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran

Khosro Keshavarz 1 , 2 , Abbas Kebriaeezadeh 1 , Seyed Moayed Alavian 3 , Ali Akbari Sari 1 , 4 , Farid Abedin Dorkoosh 1 , Maryam Keshvari 5 , Seyed Ali Malekhosseini 6 , Saman Nikeghbalian 6 and Shekoufeh Nikfar 1 , *
Authors Information
1 Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
2 Health Human Resource Research Center, School of Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4 Department of Health Management and Economics, Tehran University of Medical Sciences, Tehran, IR Iran
5 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization, Tehran, IR Iran
6 Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: April 2015, 15 (4); e58832
  • Published Online: April 25, 2015
  • Article Type: Research Article
  • Received: December 9, 2014
  • Revised: February 16, 2015
  • Accepted: March 15, 2015
  • DOI: 10.5812/hepatmon.15(4)2015.25854

To Cite: Keshavarz K, Kebriaeezadeh A, Alavian S M, Akbari Sari A, Abedin Dorkoosh F, et al. Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran, Hepat Mon. 2015 ; 15(4):e58832. doi: 10.5812/hepatmon.15(4)2015.25854.

Abstract
Copyright © 2015, Kowsar Corp.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Kalantari H, Davari M, Akbari M, Hejazi SM, Kalantari M, Zakerin S, et al. The estimation of direct medical costs of treating patients with chronic hepatitis B and C in iran. Int J Prev Med. 2012; 3(3): 191-6[PubMed]
  • 2. Lok AS. Chronic hepatitis B. N Engl J Med. 2002; 346(22): 1682-3[DOI][PubMed]
  • 3. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 4. Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006; 44(1): 108-16[DOI][PubMed]
  • 5. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997; 337(24): 1733-45[DOI][PubMed]
  • 6. Lai CL. Chronic hepatitis B in Hong Kong: immunization strategies for the control of hepatitis B virus infection. Hepat B Asian Pac Region. 1997; 1: 79-87
  • 7. Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. Arch Clin Infect Dis. 2010; 5(1): 51-61
  • 8. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
  • 9. Qirbi N, Hall AJ. Epidemiology of hepatitis B virus infection in the Middle East. East Mediterr Health J. 2001; 7(6): 1034-45[PubMed]
  • 10. Shahnaz S, Reza B. Risk factors in chronic hepatitis B infection: a case-control study. Hepat Mon. 2005; 2005(4): 109-15
  • 11. Nguyen VT, Law MG, Dore GJ. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int. 2008; 28(4): 525-31[PubMed]
  • 12. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus infection in Iran: A systematic review. Hepat Mon. 2008; 8(4): 281-94
  • 13. Lai CL, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat. 2007; 14 Suppl 1: 6-10[PubMed]
  • 14. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005; 25 Suppl 1: 3-8[DOI][PubMed]
  • 15. Kavosi Z, Zare F, Jafari A, Fattahi MR. Economic burden of hepatitis B virus infection in different stages of disease; a report from southern iran. Middle East J Dig Dis. 2014; 6(3): 156-61[PubMed]
  • 16. Mehrazmay A, Alavian SM, Moradi-Lakeh M, Mokhtari Payam M, Hashemi-Meshkini A, Behnava B, et al. Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in iran. Hepat Mon. 2013; 13(9)[DOI][PubMed]
  • 17. Keshavarz K, Kebriaeezadeh A, Meshkini AH, Nikfar S, Mirian I, Khoonsari H. Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business? Daru. 2012; 20(1): 62[DOI][PubMed]
  • 18. Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Hakkaart-van Roijen L. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ. 2009; 10(1): 39-45[PubMed]
  • 19. Haghparast-Bidgoli H, Kiadaliri AA, Skordis-Worrall J. Do economic evaluation studies inform effective healthcare resource allocation in Iran? A critical review of the literature. Cost Eff Resour Alloc. 2014; 12: 15[DOI][PubMed]
  • 20. Ong SC, Lim SG, Li SC. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. J Viral Hepat. 2009; 16(1): 53-63[PubMed]
  • 21. Tu HAT, Woerdenbag HJ, Riewpaiboon A, Kane S, Le DM, Postma MJ, et al. Cost of Illness of Chronic Hepatitis B Infection in Vietnam. Value in Health Regional Issues. 2012; 1(1): 23-8[DOI]
  • 22. The Rate Currency. 2013;
  • 23. Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian MA, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. Daru. 2013; 21(1): 50[DOI][PubMed]
  • 24. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2009; 14(4): 249-58[PubMed]
  • 25.
  • 26. Fazli ZFB, Fatemeh S, Abdi A, Pourhosseingholi MA, Taghinejad H. Studying of liver cancer mortality and morbidity burden in Iran. Sci J Ilam Univ Med Sci. 2012; 4(20): 117-22
  • 27. Babamahmoodi FB, Haghshenas M, Haghshenas M. Treatment of chronic hepatitis B virus infection. J Clin Excell. 2013; 1(1): 1-25
  • 28. Iran Government news Network . Iran budget law. 2013;
  • 29. Kowdley KV. The cost of managing chronic hepatitis B infection: a global perspective. J Clin Gastroenterol. 2004; 38(10 Suppl 3)-3[PubMed]
  • 30. Hsieh CR, Kuo CW. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol. 2004; 38(10 Suppl 3)-52[PubMed]
  • 31. Li SC, Ong SC, Lim SG, Yeoh KG, Kwong KS, Lee V, et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol. 2004; 38(10 Suppl 3)-43[PubMed]
  • 32. Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol. 2004; 38(10 Suppl 3)-7[PubMed]
  • 33. Nasiripour AA, Ghorbani Kalkhajeh S. The Challenges of Increasing Out of Pocket Payment in Healthcare System. Int J Healthcare, Healthc Equity. 2014; 1(2)
  • 34. Varmaghani M, Arab M, Zeraati H. The most important factors that patient choose public or private hospital. MSc thesis. 2008;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments